验证数据展示
经过测试的应用
Positive FC detected in | human PBMCs |
推荐稀释比
应用 | 推荐稀释比 |
---|---|
This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood. | |
Sample-dependent, Check data in validation data gallery. |
产品信息
CL594-65632 targets CD155/PVR in FC applications and shows reactivity with human samples.
经测试应用 | FC Application Description |
经测试反应性 | human |
免疫原 | SK-N-AS human neuroblastoma cells 种属同源性预测 |
宿主/亚型 | Mouse / IgG2a |
抗体类别 | Recombinant |
产品类型 | Antibody |
全称 | poliovirus receptor |
别名 | PVR, Nectin like protein 5, NECL-5, NECL5, Necl 5 |
计算分子量 | 45 kDa |
GenBank蛋白编号 | BC015542 |
基因名称 | CD155/PVR |
Gene ID (NCBI) | 5817 |
偶联类型 | CoraLite®594 Fluorescent Dye |
最大激发/发射波长 | 588 nm / 604 nm |
形式 | Liquid |
纯化方式 | Protein A purification |
储存缓冲液 | PBS with 0.09% sodium azide and 0.5% BSA , pH 7.3 |
储存条件 | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
背景介绍
CD155, also known as PVR, is a type I transmembrane glycoprotein in the immunoglobulin superfamily. It contains three extracellular immunoglobulin-like domains, D1-D3, of which D1 is recognized by the virus. Mature human CD155 consists of a 323 amino acid extracellular domain with one N-terminal V-type and two C2-type Ig-like domains, a 24 amino acid transmembrane segment, and a 50 amino acid cytoplasmic tail. CD155 is thought to play a role in adhesion by interaction with the ECM component vitronectin as well as a role in NK killing of tumor cells. CD155 binds to two receptors of NK cells, CD96 and CD226, and accumulates at cell-cell contact sites, leading to the formation of mature immune synapses between NK cells and target cells. CD155 serves as the entry receptor for poliovirus and thereby mediates human susceptibility to poliovirus infection.
实验方案
Product Specific Protocols | |
---|---|
FC protocol for CL594 CD155/PVR antibody CL594-65632 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |